More about

Lung Function

News
June 27, 2024
1 min read
Save

FDA approves Ohtuvayre as maintenance treatment for COPD

FDA approves Ohtuvayre as maintenance treatment for COPD

The FDA has approved the phosphodiesterase enzyme 3 and 4 inhibitor ensifentrine, now named Ohtuvayre, for treating adults with COPD, according to a manufacturer-issued press release.

News
June 20, 2024
3 min read
Save

Buloxibutid well tolerated, increases lung function in IPF

Buloxibutid well tolerated, increases lung function in IPF

SAN DIEGO — Among patients with idiopathic pulmonary fibrosis, twice-daily buloxibutid for 36 weeks significantly improved FVC, according to research presented at the American Thoracic Society International Conference.

News
June 11, 2024
3 min read
Save

Young smoker CT scans show lung abnormalities, lung function loss over 3 years

Young smoker CT scans show lung abnormalities, lung function loss over 3 years

SAN DIEGO — Lung abnormalities appeared more frequently on CT scans from young current smokers vs. never smokers, according to research presented at the American Thoracic Society International Conference.

News
June 10, 2024
1 min read
Save

Adults with food insecurity have reduced lung function, elevated COPD symptom burden

Adults with food insecurity have reduced lung function, elevated COPD symptom burden

SAN DIEGO — Lung function decreased and COPD symptom burden increased among adults with vs. without food insecurity, according to research presented at the American Thoracic Society International Conference.

News
June 03, 2024
4 min read
Save

Hedgehog pathway inhibitor safe, improves lung function in IPF

Hedgehog pathway inhibitor safe, improves lung function in IPF

SAN DIEGO — After receiving a hedgehog pathway inhibitor for 12 weeks, adults with idiopathic pulmonary fibrosis had better lung function, according to research presented at the American Thoracic Society International Conference.

News
May 31, 2024
5 min read
Save

Dupilumab lowers exacerbations, betters lung function in COPD with type 2 inflammation

Dupilumab lowers exacerbations, betters lung function in COPD with type 2 inflammation

SAN DIEGO — With dupilumab vs. placebo, adults with moderate to severe COPD and type 2 inflammation experienced fewer exacerbations, according to research presented at the American Thoracic Society International Conference.

News
May 30, 2024
3 min read
Save

Race-neutral lung function equations alter disease classification, disability compensation

Race-neutral lung function equations alter disease classification, disability compensation

SAN DIEGO — Millions of individuals had different clinical, occupational and financial outcomes with race-neutral vs. -specific lung function equations, according to a presentation at the American Thoracic Society International Conference.

News
May 29, 2024
4 min read
Save

Dupilumab associated with significant reductions in mucus plugging, volume

Dupilumab associated with significant reductions in mucus plugging, volume

SAN DIEGO — Patients with asthma experienced significant reductions in mucus airway plugging and mucus volume with dupilumab, according to a presentation at the American Thoracic Society International Conference.

News
May 29, 2024
2 min read
Save

Biologics lower exacerbations, hospitalizations in COPD, Th2 inflammation

Biologics lower exacerbations, hospitalizations in COPD, Th2 inflammation

SAN DIEGO — After 1 year of biologic therapy, patients with COPD and Th2 inflammation experienced fewer exacerbations and hospitalizations, according to research presented at the American Thoracic Society International Conference.

News
May 23, 2024
6 min read
Save

Tezepelumab decreases exacerbation rate, improves lung function, quality of life in COPD

Tezepelumab decreases exacerbation rate, improves lung function, quality of life in COPD

SAN DIEGO — Among patients with moderate to very severe COPD receiving tezepelumab vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented at the American Thoracic Society International Conference.

View more